Payer control of oncology drug utilization and costs is shifting. 

HMP MAI helps subscribers understand how payers are pursuing greater control and where they are most likely to succeed. Our primary and secondary research illuminates the strategies that the “vertical payers,” other nationals, and key regional plans attempt (and anticipate) to employ most, how effective those strategies are, and where they think cancer drug rebating is headed. These business-critical insights help subscribers shape their payer engagements and secure drug coverage and productive relationships.

This content is for subscribing clients only.

Become a Subscriber